Increasing Prevalence of Chronic Diseases to Boost the Market
Some of the most common chronic diseases include heart disease, stroke, type 2 diabetes, obesity, cancer, and arthritis. According to the Center for Disease Control and Prevention (CDC), in the United States, seven of the top 10 causes of death in 2014 were chronic diseases. Cancer and heart disease together accounted for an approximate of 46% of all deaths. It was also reported that about half of the adults in the United States had one or more chronic conditions and one if four had more than two chronic conditions. Moreover, these numbers are expected to increase in the next 10 years. Since the adoption rate of injectable drug delivery devices is high among the population suffering from diseases like diabetes and heart-related disorders, the increasing prevalence of chronic diseases is expected to contribute to the growth of injectable drug delivery technology market in the forecast period.
The benefits and convenience of the use of injections are also contributing to the growth of the market.
Injuries and Infections Caused by Needles
Injuries and infections due to needles are acting as a major restraint for the global injectable drug delivery technology market. According to the Occupational Safety & Health Administration (OSHA) estimates, 5.6 million workers in the healthcare industry are at a risk of needle injuries. Moreover, there has been an increment in the infections caused by needles over the past few years. Therefore with the increasing injuries and the infections caused by needles, there is reluctance among people to use injections, hampering the growth of the injectable drug delivery technology market.
Growing use of alternative drug delivery methods along with safety concerns associated with the use of injections is also restraining the market.
United States Leads the Market in North America
The United States injectable drug delivery technology market held the largest market share in 2017 in North America due to the rising incidence of cardiovascular diseases, growing geriatric population, and the strong presence of industry players in that region.
Key Developments in the Market:
- April 2017: BD (Becton, Dickinson, and Company) and C. R. Bard, Inc., entered into a definitive agreement.
Reasons to Purchase the Report
- Follow the current and future North America injectable drug delivery technology market in the developed and emerging markets.
- Analyzing various perspectives of the market with the help of Porter’s Five Forces Analysis.
- Identify the segment that is expected to dominate the market.
- Identify the regions that are expected to witness the fastest growth during the forecast period.
- Identify the latest developments, market shares, and strategies employed by the major market players.
- 3-month analyst support along with the Market Estimate sheet (in Excel).
This report can be customized to meet your requirements.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1.1 Increasing Prevalence of Chronic Diseases
6.1.2 Benefits and Convenience with the Use of Injections
6.2.1 Injuries and Infections Caused by Needles
6.2.2 Growing Use of Alternative Delivery Methods
6.2.3 Safety Concerns
6.4 Key Challenges
7. Market Segmentation
7.1 By Type
18.104.22.168 Self-injection Devices
22.214.171.124 Conventional Injection Devices
126.96.36.199 Conventional Drug Delivery
188.8.131.52 Novel Drug Delivery
7.2 By Application
7.2.1 Cardiovascular Disease
7.2.3 Regenerative Medicine
7.2.5 Autoimmune Disorders
7.2.6 Hepatitis B
7.3 By Geography
7.3.1 North America
184.108.40.206 United states
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Antares Pharmaceutical Inc.
9.2 Baxter International
9.3 Becton, Dickinson, and Company
9.4 Elcam Medical
9.5 Eli Lilly and Company
9.6 Unilife Corporation
9.7 West Pharmaceutical Services Inc.
*List not Exhaustive
10. Future of the Market